Cullinan Associates Inc. Has $1.85 Million Holdings in Pfizer Inc. $PFE

Key Points

• Cullinan Associates Inc. increased its holdings in Pfizer Inc. by 18.3%, owning 76,501 shares valued at $1.85 million as of the latest reporting period.
• Institutional investors and hedge funds own 68.36% of Pfizer's stock, indicating strong institutional interest in the company.
• Analysts have mixed ratings on Pfizer, with a consensus target price of $28.41 and several recent reports issuing hold or neutral ratings.

Cullinan Associates Inc. lifted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 18.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 76,501 shares of the biopharmaceutical company's stock after purchasing an additional 11,847 shares during the period. Cullinan Associates Inc.'s holdings in Pfizer were worth $1,854,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of PFE. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the 1st quarter worth $27,000. North Capital Inc. bought a new stake in shares of Pfizer during the 1st quarter worth $28,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer during the 1st quarter worth $28,000. Horizon Financial Services LLC bought a new stake in shares of Pfizer during the 1st quarter worth $35,000. Finally, WPG Advisers LLC bought a new stake in shares of Pfizer during the 1st quarter worth $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a report on Saturday, September 27th. UBS Group reissued a "neutral" rating and issued a $28.00 price target on shares of Pfizer in a report on Wednesday. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Bank of America increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday. Finally, Morgan Stanley increased their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $28.41.

Pfizer Trading Up 1.1%

PFE opened at $27.37 on Monday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $155.59 billion, a PE ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The firm has a 50-day moving average price of $24.67 and a two-hundred day moving average price of $24.12.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.